Laboratory monitoring of hemophilia A treatments: new challenges
Open Access
- 12 May 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (9) , 2111-2118
Abstract
Monitoring factor VIII (FVIII) activity has traditionally been complicated by discrepancies between assays for the various sorts of FVIII molecules. The advent of novel nonfactor therapies (emicizumab, fitusiran, and anti-tissue factor pathway inhibitor antibodies) in hemophilia A poses a new level of difficulty on the laboratory monitoring of these patients. To use the correct assays and for a proper interpretation of their results, it is pertinent to understand the mode of action of these nonfactor agents. Furthermore, the biochemical consequences for the different types of activity assays (whether it be specific FVIII activity assays or global coagulation assays) should be taken into account as well. In this review, these aspects will be discussed. In addition, the use of various animal models to estimate FVIII-equivalence of the nonfactor therapies will be presented.Keywords
This publication has 66 references indexed in Scilit:
- Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia modelBlood, 2012
- Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complexHaematologica, 2012
- The phenotypic and genetic assessment of antithrombin deficiencyInternational Journal of Laboratory Hematology, 2011
- Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profileJournal of Thrombosis and Haemostasis, 2010
- A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI)Journal of Thrombosis and Haemostasis, 2005
- Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and BThrombosis and Haemostasis, 2005
- Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assaysJournal of Thrombosis and Haemostasis, 2004
- A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standardsJournal of Thrombosis and Haemostasis, 2003
- Antisense genes in plants: an overviewGene, 2003
- An anti-sense chalcone synthase gene in transgenic plants inhibits flower pigmentationNature, 1988